A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer.

Long-term survival in epithelial ovarian cancer remains problematic despite multimodality therapy. A fundamental difficulty is the development of tumor resistance to platinum compounds. Analogs have been developed that demonstrate activity in platinum-resistant cell lines both in vitro and in vivo. Lobaplatin (D-19466), a third-generation compound, demonstrates significant activity in carboplatin and cisplatin-resistant cell lines. Lobaplatin was given to 17 assessable patients with platinum-refractory ovarian cancer. The drug was initially administered at a dose of 50 mg/m2 but was later reduced to 40 mg/m2 because of excessive thrombocytopenia. Nine patients required red cell transfusions during therapy. Cycles were repeated every 21-35 days (median cycle length 28 days). No objective responses were observed. Lobaplatin has no activity in platinum-resistant epithelial ovarian cancer.
AuthorsJ J Kavanagh, C L Edwards, R S Freedman, M B Finnegan, O Balat, D Tresukosol, K Burk, S Loechner, M Hord, J L Franklin
JournalGynecologic oncology (Gynecol Oncol) Vol. 58 Issue 1 Pg. 106-9 (Jul 1995) ISSN: 0090-8258 [Print] UNITED STATES
PMID7789874 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Cyclobutanes
  • Organoplatinum Compounds
  • Platinum
  • lobaplatin
  • Adult
  • Aged
  • Antineoplastic Agents (therapeutic use)
  • Cyclobutanes (therapeutic use)
  • Drug Resistance
  • Female
  • Humans
  • Middle Aged
  • Organoplatinum Compounds (therapeutic use)
  • Ovarian Neoplasms (drug therapy)
  • Platinum (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: